

Updated January 22, 2021

## COVID-19 CODING QUICK REFERENCE FOR PARTICIPATING PROVIDERS

COVID-19 continues to impact communities in the Mid-Atlantic region, and throughout the United States and world. We appreciate your partnership on our response to addressing the spread of the virus; and providing prompt and compassionate care to our members and patients.

This document contains coding information for COVID-19 coronavirus.

### COVID-19 Testing-Related Services Modifier “CS”

The “CS” modifier should be used to identify COVID-19 testing-related services, which may include medical visits that:

- result in the administration of or an order for a COVID-19 test
- are related to providing a COVID-19 test or to the evaluation of a member for purposes of determining the need for a COVID-19 test

Use the “CS” modifier on applicable claim lines to identify the services subject to the cost-sharing waiver for COVID-19 testing-related services and visits. This modifier may be used on professional and institutional claim forms.

### COVID-19-Associated Lab Test Coding

All COVID-19 lab tests should be coded using the following procedure codes. These tests are no-charge to all members.

Procedure Codes	Description
<b>0202U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected <b>(Effective 5/20/2020)</b>
<b>0223U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected <b>(Effective 6/25/2020)</b>
<b>0224U</b>	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed <b>(Effective 6/25/2020)</b>
<b>0225U</b>	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected <b>(Effective 8/10/2020)</b>
<b>0226U</b>	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum <b>(Effective 8/10/2020)</b>

Procedure Codes	Description
<b>0240U</b>	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected <b>(Effective 10/6/2020)</b>
<b>0241U</b>	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected <b>(Effective 10/6/2020)</b>
<b>86328</b>	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
<b>86408</b>	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen <b>(Effective 8/10/2020)</b>
<b>86409</b>	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer <b>(Effective 8/10/2020)</b>
<b>86413</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative <b>(Effective 9/10/2020)</b>
<b>86769</b>	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
<b>87426</b>	Severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) <b>(Effective 6/25/2020)</b>
<b>87428</b>	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B <b>(Effective 11/10/2020)</b>
<b>87635</b>	Infectious agent detection by (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [COVID-19] <b>(Do not use this procedure for Medicare members)</b>
<b>87636</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique <b>(Effective 10/6/2020)</b>
<b>87637</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique <b>(Effective 10/6/2020)</b>
<b>87811</b>	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) <b>(Effective 10/6/2020)</b>
<b>D0604</b>	Antigen testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/2021)</b>

Procedure Codes	Description
<b>D0605</b>	Antibody testing for a public health related pathogen, including coronavirus <b>(Effective 1/1/2021)</b>
<b>G2023</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source. <b>(Effective 3/1/2020)</b>
<b>G2024</b>	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a SNF or by a laboratory on behalf of an HHA, any specimen source. <b>(Effective 3/1/2020)</b>
<b>U0001</b>	Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Test Panel <b>(Use only for tests performed by CDC)</b>
<b>U0002</b>	Private labs (e.g. Quest) 2019-nCoV Coronavirus, SARS-CoV-2/2019- nCoV (COVID-19) <b>(Use for Medicare members or Commercial members)</b>
<b>U0003</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R
<b>U0004</b>	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R
<b>U0005</b>	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. (List separately in addition to either HCPCS code U0003 or U0004) <b>(Effective 1/1/2021)</b>

Other Associated Diagnostic Testing	
Procedure Codes	Description
<b>87400</b>	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; <b>Influenza, A or B, each</b>
<b>87486</b>	Infectious agent detection by nucleic acid (DNA or RNA); <b>Chlamydia pneumoniae</b> , amplified probe technique
<b>87581</b>	Infectious agent detection by nucleic acid (DNA or RNA); <b>Mycoplasma pneumoniae</b> , amplified probe technique
<b>87633</b>	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets

Other	
Procedure Codes	Description
<b>99072</b>	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease <b>(Effective 9/10/2020)</b>

Monoclonal Antibody Therapy Administration	
Procedure Codes	Description
<b>M0243</b>	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
<b>M0239</b>	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring

Monoclonal Antibody Therapy Drug Supply	
Procedure Codes	Description
<b>Q0243</b>	Injection, casirivimab and imdevimab, 2400 mg <b>(Provided at no cost and should not billed on a claim)</b>
<b>Q0239</b>	Injection, bamlanivimab-xxxx, 700 mg <b>(Provided at no cost and should not billed on a claim)</b>

### COVID-19 ICD-10 Diagnosis Coding

Proper diagnosis is needed to represent the care provided and ensure we can identify and track the at-risk population. As a reminder, effective March 6, 2020, all visits associated with screening, testing, diagnosis and treatment for the COVID-19 will be no charge for all members. The no charge coverage includes visits, associated labs, radiology and vaccine (when available) if members suspect or were exposed to the coronavirus or are under investigation for exposure to COVID-19. Medically necessary treatment of COVID-19 is also being covered at no-charge.

Please use the scenarios below to find the most specific and accurate diagnosis code. Using these codes will support no-charge claims processing associated with COVID-19 screening, diagnosis, testing and treatment services.

Care Scenario	Use ICD-10 DX Code:
<b>Concern about a possible exposure to COVID-19, but ruled out after evaluation</b>	<b>Z03.818:</b> Encounter for observation for suspected exposure to other biological agents ruled out
<b>Actual or suspected exposure to someone who is infected with COVID-19; Person under investigation</b>	<b>Z20.822:</b> Contact with and (suspected) exposure to COVID-19 <b>(Effective 1/1/2021)</b> <b>Z20.828:</b> Contact with and (suspected) exposure to other viral communicable diseases
<b>Asymptomatic Patient screened for COVID-19</b>	<b>Z11.52:</b> Encounter for screening for COVID-19 <b>(Effective 1/1/2021)</b> <b>Z11.59:</b> Encounter for screening for other viral diseases
<b>Confirmed COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease
<b>Case of acute bronchitis confirmed as due to COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease <b>and</b> <b>J20.8:</b> Acute bronchitis due to other specified organisms
<b>Cases of Bronchitis not otherwise specified (NOS) due to the COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease <b>and</b> <b>J40:</b> Bronchitis, not specified as acute or chronic
<b>Cases of lower respiratory infection, not otherwise specified (NOS) or an acute respiratory infection, NOS associated with confirmed COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease <b>and</b> <b>J22:</b> Unspecified acute lower respiratory infection
<b>Cases of respiratory infection, NOS due to COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease <b>and</b> <b>J98.8:</b> Other specified respiratory disorders
<b>Cases of ARDS (Acute Respiratory Distress Syndrome) due to COVID-19</b>	<b>U07.1:</b> 2019-nCoV acute respiratory disease <b>and</b> <b>J80:</b> Acute respiratory distress syndrome,

On February 20, 2020 the CDC announced a new ICD-10, U07.1: 2019-nCoV acute respiratory that became effective on April 1, 2020 and may not be used for billed claims until that date.

For more information related to CDC's ICD-10-CM Official Coding Guidelines - Supplement Coding encounters related to COVID-19 Coronavirus Outbreak please go to <https://www.cdc.gov/coronavirus>.

### COVID-19 Vaccinations

Kaiser Permanente will cover the administration of any FDA-approved COVID-19 vaccine at no cost-share to all commercial and Medicaid members (see Medicare Reimbursement). Providers may bill for the administration of the vaccine but not the cost of the vaccine as they are provided at no cost by the Federal government. No authorization is required for the administration of COVID-19 vaccinations.

**Medicare Reimbursement COVID-19 Vaccinations and Monoclonal Antibody Therapy –**

Original Medicare will reimbursement COVID-19 vaccine administration and monoclonal antibody therapy administration (MAB) costs. Therefore, claims for COVID-19 vaccination and MAB administration should be submitted to Original Medicare via the appropriate Medicare Administrative Contractors directly and not to Kaiser Permanente. This provision is for COVID-19 vaccination and MAB administration only. All other Medicare Advantage claims including COVID-19 screening, testing, diagnosis and treatment will continue to be submitted to Kaiser Permanente for reimbursement. For additional information, go to:

- <https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>
- <https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion#Payment>

**All COVID-19 vaccine administration costs should be billed using the following codes:**

Procedure Codes	Description
<b>0001A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; <b>first dose (Pfizer)</b>
<b>0002A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; <b>second dose (Pfizer)</b>
<b>0011A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; <b>first dose (Moderna)</b>
<b>0012A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; <b>second dose (Moderna)</b>

We will provide any additional information regarding COVID-19 coding to you as quickly as possible.